Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Willis Towers Watson Public Limited Company's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $26.8B | |
|---|---|---|
| Revenue (ttm) | 10.1B | |
| Net income (ttm) | 1.6B | |
| EPS (ttm) | $16.3 | |
| Shares out | 92.9M | |
| P/E (trailing) | 19.7x | |
| P/E (forward) | 17.4x | |
| Dividend | $3.84 (1.20%) | |
| Volume | 613,580 | |
| Beta | 0.47 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $8.83B | $8.73B | $9.30B | $9.74B | $9.52B | +1.9% |
| Gross profit | $3.75B | $3.80B | $7.67B | $4.43B | $4.08B | +2.2% |
| Operating income | $2.20B | $1.18B | $1.37B | $627.0M | $2.23B | +0.4% |
| Net income | $4.22B | $1.01B | $1.06B | $-98.0M | $1.61B | -21.5% |
| EPS (diluted) | $32.78 | $8.98 | $9.95 | $-0.96 | $16.26 | -16.1% |
| EBITDA | $3.55B | $2.03B | $1.37B | $823.0M | $2.68B | -6.9% |
| R&D | $0 | $0 | $0 | — | — | -34.2% |
| SG&A | $6.93B | $6.84B | — | — | — | -1.2% |
Recent company headlines from major financial publishers.
The modal base case path reflects steady mid-single-digit organic growth supported by recurring corporate benefits administration in Health, Wealth & Career and balanced international commercial placement. The Propel restructuring program steadily scales operating margins over the transformation horizon, while disciplined annual share repurchases compound per-share cash flow, supporting the composite fair value midpoint.
Under the upside scenario, the $625M Propel restructuring program rapidly eliminates administrative bottlenecks, enabling brokers and consultants to win competitive market share from peers. Enterprise adjusted operating margins reach 30.0% by FY2028, supported by 35% in Health, Wealth & Career and 30% in Risk & Broking. Accelerated free cash flow expansion finances heavy share repurchases, compounding diluted EPS toward the top of our valuation range.
| Ke ↓ / g → | 2.3% | 2.5% | 2.8% | 3.0% | 3.3% |
|---|---|---|---|---|---|
| 6.5% | $470 | $487 | $507 | $531 | $559 |
| 7.0% | $435 | $447 | $462 | $479 | $498 |
| 7.5% | $406 | $416 | $427 | $440 | $454 |
| 8.0% | $383 | $391 | $400 | $409 | $420 |
| 8.5% | $364 | $370 | $377 | $385 | $393 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |